Possible agent for COVID-19 treatment: Rifampicin.

ArticleAçık Erişim
RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/20347Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.5501/wjv.v11.i5.391Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorAydin, OC
dc.contributor.authorAydın, S
dc.contributor.authorBarun, S
dc.date.accessioned2026-10-18T21:14:16.712077211Z
dc.date.available2026-10-18T21:14:16.712077211Z
dc.date.issued2022
dc.identifier.doi10.5501/wjv.v11.i5.391
dc.identifier.endpage393
dc.identifier.issue5
dc.identifier.pmcidPMC9523331
dc.identifier.pmid36188747
dc.identifier.startpage391
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/20347
dc.identifier.volume11
dc.language.isoen
dc.relation.ispartofWorld journal of virology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titlePossible agent for COVID-19 treatment: Rifampicin.
dc.typeArticle
dspace.entity.typePublication
rdl.departmentDepartment of Medical Pharmacology, Erzincan University, Mengucek Gazi Education and Research Hospital, Erzincan 24100, Turkey. ozlemclk_89@hotmail.com. | Department of Radiology, Erzincan University, Erzincan 24100, Turkey.
rdl.source.indexPUBMED